Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3052W HIGH $3.62
Volume
917.66 K
Value Traded
1.06 M
Short % Float
9.08%
-3.45%Week
-19.19%1 Month
-54.2%3 Month
-87.99%6 Month
-41.44%5 Year
-41.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
27.47 M
EPS (TTM)
-0.50
P/E Ratio
-
Ent. Value
-15.52 M
Total Shares
91.89 M
Float Shares
76.10 M
Insiders
17.17%
Institutions
57.63%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CNTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Context Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Context Therapeutics Inc.
235Total events
7Upcoming
52Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedCT-202Trial
First patient dosed in Phase 1 trial of CT-202
Nectin-4 expressing recurrent, unresectable or metastatic refractory/resistant urothelial, colorectal and triple-negative breast cancerssource ↗
◆Trial InitiationCT-202Trial
Phase 1 clinical trial initiation for CT-202 expected in Q3 2026
solid tumorssource ↗
▲First Patient DosedCT-202Trial
First patient dosed in Phase 1 trial
urothelial, colorectal, and triple-negative breast cancerssource ↗
▲Fast Track DesignationCTIM-76Designation
FDA Fast Track Designation granted for CTIM-76 in PROC
platinum-resistant ovarian cancersource ↗
▲Topline ReadoutCTIM-76Clinical Data
Positive interim efficacy and safety results from Phase 1a dose escalation
advanced solid tumors (PROC, testicular, endometrial)source ↗
●Oral PresentationCTIM-76Presentation
Investor conference call to discuss interim data
platinum-resistant ovarian cancersource ↗
◆Interim AnalysisCTIM-76Trial
Interim data from Phase 1a trial expected
CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancerssource ↗
◆Topline ReadoutCTIM-76Clinical Data
Phase 1a interim data for CTIM-76 expected in June 2026
CLDN6-positive solid tumorssource ↗
◆Topline ReadoutCT-95Clinical Data
Initial Phase 1a data expected
pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancersource ↗
▲Oral PresentationCTIM-76Presentation
Presented interim Phase 1a safety, tolerability and efficacy data with weekly dosing
platinum-resistant ovarian cancersource ↗
▲Partnership / LicenseCT-202Corporate
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202, removing future milestones and royalties
solid tumorssource ↗
▲Partnership / LicenseCT-202Corporate
License Agreement Amendment with BioAtla removing future milestones and royalty obligations
◆Poster PresentationCT-202Presentation
Poster presentation at AACR 2026 on CT-202 preclinical data
solid tumorssource ↗
▲Fast Track DesignationCTIM-76Designation
FDA grants Fast Track Designation for CTIM-76 in PROC
platinum-resistant ovarian cancersource ↗
●IND SubmissionCT-202IND
Complete regulatory filings to support first-in-human trial initiation expected
bladder, non-small cell lung, colorectal, breast, and head and neck cancersource ↗
▲Fast Track DesignationCTIM-76Designation
FDA granted Fast Track Designation for CTIM-76 in PROC
platinum-resistant ovarian cancersource ↗
●Poster PresentationCT-202Presentation
Preclinical data for CT-202 presented at AACR 2026
Nectin-4-positive solid tumorssource ↗
▲IND ClearanceCT-202IND
Received HREC approval and CTN acknowledgement in Australia to initiate Phase 1 trial of CT-202
Nectin-4-positive solid tumorssource ↗
◆Topline ReadoutCTIM-76Clinical Data
Updated interim Phase 1a data and Phase 1b dose selection expected
ovarian, endometrial, or testicular cancersource ↗
◆Topline ReadoutCT-95Clinical Data
Initial clinical data expected mid-2026
mesothelin expressing cancerssource ↗
▲Other Regulator MilestoneCT-202Ex-US Regulatory
HREC approval and CTN acknowledgement by Australian TGA to initiate Phase 1 trial
urothelial, colorectal, and triple-negative breast cancerssource ↗
▲Trial InitiationCT-202Trial
HREC approval and CTN acknowledgement to initiate Phase 1 trial
urothelial, colorectal, and triple-negative breast cancerssource ↗
◆Topline ReadoutCTIM-76Clinical Data
Initial data from CTIM-76 Phase 1 trial expected
CLDN6-positive gynecologic and testicular cancerssource ↗
◆Poster PresentationCT-95Presentation
Trial in Progress poster for CT-95 at SITC 2025
Advanced Solid Tumorssource ↗
◆Poster PresentationCT-202Presentation
Preclinical efficacy, safety and PK data poster for CT-202 at SITC 2025
Solid Tumorssource ↗
▲Topline ReadoutCTIM-76Clinical Data
Encouraging early antitumor activity and safety from ongoing Phase 1 dose escalation
ovarian, endometrial, or testicular cancersource ↗
▲Topline ReadoutCT-95Clinical Data
Approaching target dose levels in Phase 1 dose escalation
pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancersource ↗
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat
●Poster PresentationCTIM-76Presentation
Trial in Progress poster presentation at 2025 ASCO Annual Meeting
ovarian, endometrial, and testicular cancerssource ↗
▲Enrollment UpdateCTIM-76Trial
Dosing cohort 3 of Phase 1 trial
ovarian, endometrial, and testicular cancerssource ↗
●Poster PresentationCTIM-76Presentation
Trial in Progress poster for CTIM-76 Phase 1 at ASCO 2025
solid tumors (CLDN6+)source ↗
Past FDA Catalysts and PDUFA Decisions
How CNTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | CT-95 (MSLN x CD3) | Phase 1a interim results | Phase 1a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$5M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 68%
Micro Cap(rank 448 of 658)
Percentile Rank
Context Therapeutics Inc. faces pipeline headwinds (30/100), with $260M risk-adjusted pipeline value, led by CT-202 in Triple Negative Breast Cancer (TNBC) (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CT-202 Small moleculeNCT07545122 | Triple Negative Breast Cancer (TNBC) | Phase 1 | RECRUITING | 162 | Jan 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every CNTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CTIM-76 Fast Track | platinum-resistant ovarian cancer | Phase 1 | 2026-06-15 | overall response rate: 29%; disease control rate: 57%; CRS events: 11%Read More | Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pasternak AndyDirector | Grant/Award | 45,000 45,000 held | $0.00 | 06/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CNTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0.1 % (-66.7 %) | 4.11 M | 7.42 M |
CNTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CNTX ranks across every disease it competes in
Competitive Position is a premium feature
See how CNTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCNTX News
CNTXContext Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
Context Therapeutics has announced the dosing of the first patient in its Phase 1 trial for CT-202, a bispecific antibody targeting Nectin-4. This trial aims to evaluate CT-202's safety, tolerability, and preliminary efficacy in patients with specific cancers. The company anticipates reporting initial data in late 2027.
Read more →CNTX▼ -27.3%on this news
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Context Therapeutics reported its Q2 2026 financial results, highlighting progress in its clinical pipeline, particularly with CTIM-76 and CT-202. The company has received Fast Track Designation for CTIM-76 and plans to initiate a Phase 1 trial for CT-202 soon. Despite a net loss, the company has sufficient cash to fund operations into late 2027.
Read more →CNTXContext Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Inc. has announced the granting of a stock option award to a new employee as an inducement for employment. This award includes 146,000 shares at an exercise price of $0.70 per share, with a 10-year term and a vesting schedule over four years. The grant complies with Nasdaq Listing Rule 5635(c)(4).
Read more →CNTX▲ +9.8%on this news
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Context Therapeutics Inc. has been added to the Russell 2000 and Russell 3000 Indexes, effective June 26, 2026. This inclusion reflects the company's standing in the market as a clinical-stage biopharmaceutical firm focused on T cell engaging bispecific antibodies for solid tumors. The Russell Indexes serve as benchmarks for investment strategies and highlight the company's growth potential.
Read more →CNTX▼ -51.1%on this news
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
Context Therapeutics announced positive interim results from its Phase 1 trial of CTIM-76, a bispecific antibody for platinum-resistant ovarian cancer. The study showed a 29% overall response rate among patients, with a favorable safety profile. The drug has received FDA Fast Track Designation, and the company plans to explore a Q3W dosing schedule in future trials.
Read more →CNTX▲ +13.3%on this news
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
Context Therapeutics Inc. announced its upcoming presentation at the Jefferies Global Healthcare Conference on June 3, 2026. The company will showcase its advancements in T cell engaging bispecific antibodies for solid tumors. Additionally, Context granted stock options to a new employee, reflecting its growth strategy. However, the company acknowledges potential risks in its forward-looking statements.
Read more →CNTXContext Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context Therapeutics has amended its license agreement with BioAtla, allowing it to buy out future milestones and royalties for the CT-202 program. In return, Context will make a total payment of $6.5 million, thereby gaining full economic rights to CT-202, an antibody targeting Nectin-4, which is implicated in various solid tumors. The Phase 1 clinical trial of CT-202 is expected to commence in the third quarter of 2026, promising potential opportunities for long-term value as the company advances its development efforts. However, there are specific risks concerning the associated adverse events with Nectin-4 targeting.
Read more →CNTXContext Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
Context Therapeutics has amended its exclusive license agreement with BioAtla for CT-202, enabling it to obtain full economic rights. This move includes an upfront payment of $4.5 million, with an additional payment of $2 million due in August 2026. The company anticipates initiating a Phase 1 clinical trial for CT-202 in the third quarter of 2026. However, CT-202 is linked to potential adverse events and the company faces various operational risks moving forward.
Read more →CNTXContext Therapeutics Reports First Quarter 2026 Operating and Financial Results
Context Therapeutics has reported its financial results for the first quarter of 2026, highlighting a strong cash position of $54.5 million to fund operations into mid-2027. The company anticipates key clinical data from its ongoing studies, including CTIM-76 and CT-95, with updates expected later this year. Additionally, Context received FDA Fast Track Designation for CTIM-76, marking a significant milestone in treatment development for ovarian cancer. However, the company recorded a net loss of $8.7 million, which has increased compared to the same period last year, raising concerns about rising operational costs.
Read more →CNTXContext Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Context Therapeutics has announced that its bispecific antibody CTIM-76 has received Fast Track Designation from the FDA for the treatment of platinum-resistant ovarian cancer. This designation is designed to accelerate the development and review of therapies that meet serious unmet medical needs. Context is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of CTIM-76, with interim data anticipated in June 2026. The designation highlights the potential of CTIM-76 to significantly impact patients who have exhausted standard treatment options.
Read more →CNTX▲ +5.3%on this news
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Context Therapeutics reported its financial results for 2025, highlighting significant advancements in its bispecific antibody pipeline. The company anticipates interim data for CTIM-76 in June 2026 and CT-95 in September 2026. With a cash balance of $66 million, Context expects to fund operations into mid-2027 and continue delivering clinical updates throughout 2026.
Read more →CNTXContext Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
Context Therapeutics Inc. announced it will be presenting a poster at the AACR Annual Meeting 2026, showcasing preclinical data for its bispecific antibody CT-202. This antibody targets Nectin-4, a protein associated with several solid tumors, and aims to enhance therapeutic efficacy in the tumor microenvironment. Scheduled for April 21, 2026, the presentation will contribute to the company's commitment to advancing novel cancer therapies. Potential risks related to CT-202 include adverse effects like neuropathy and rash.
Read more →CNTXContext Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Inc. has announced its participation in several upcoming investor conferences, showcasing its commitment to engaging with investors. The company is focused on developing T cell engaging bispecific antibodies for solid tumors. Live webcasts of the presentations will be accessible on their website, with replays available for 90 days.
Read more →CNTX▲ +6.9%on this news· ran to +26% by day 3
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
Context Therapeutics has announced the granting of non-qualified stock options to two new employees as an inducement for accepting employment. The awards, totaling 120,000 shares, were granted outside of the company's long-term incentive plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and vest over four years.
Read more →CNTX▼ -5.3%on this news· ran to +18% by day 3shared move
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Inc. announced the grant of non-qualified stock options to two newly hired employees as part of its inducement offers under Nasdaq Listing Rule 5635(c)(4). A total of 120,000 shares were awarded, with exercise prices set according to recent closing prices of the company's stock. The options come with a 10-year term and a four-year vesting schedule, reinforcing the company's aim to attract and retain talent in the competitive biopharmaceutical industry.
Read more →CNTXContext Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
Context Therapeutics showcased its CT-95 and CT-202 programs at the SITC 40th Annual Meeting. CT-95 targets mesothelin, while CT-202 focuses on Nectin-4, both aiming to enhance T cell engagement against solid tumors. The company plans to provide initial Phase 1a data for CT-95 by mid-2026 and initiate a first-in-human trial for CT-202 in Q2 2026.
Read more →CNTX▼ -5.3%on this newsshared move
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Context Therapeutics reported promising results from its ongoing Phase 1 trials for CTIM-76 and CT-95, indicating encouraging antitumor activity. The company holds $76.9 million in cash as of September 30, 2025, which is expected to fund operations into 2027. CEO Martin Lehr expressed optimism about the future of their T cell engaging bispecific antibodies.
Read more →CNTX▲ +10%on this news· ran to +27% by day 3
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Context Therapeutics Inc. has announced two poster presentations at the SITC 40th Annual Meeting, scheduled for November 7-9, 2025. The presentations will feature a Trial in Progress for the Phase 1 clinical trial of CT-95, a bispecific antibody targeting mesothelin, and preclinical data on CT-202, which targets Nectin-4. These developments highlight the company's commitment to advancing its T cell engaging bispecific antibodies for solid tumors.
Read more →About Context Therapeutics Inc.
Headquarters2001 MARKET STREET, PHILADELPHIA, PA, 19103
BIOPHARMAWATCH ELITE PLUS
Trade the next CNTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime